Dr. Daver on Results of a Combination Study With Azacitidine|Nivolumab in AML

Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the results of a phase Ib/II study that evaluated the combination of azacitidine and nivolumab (Opdivo) in patients with relapsed/refractory acute myeloid leukemia.

Website:
Twitter:
Facebook:
LinkedIn:

cancer,oncology,